Javascript must be enabled to continue!
Advanced Papillary Serous Carcinoma of the Uterine Cervix: A Case with a Remarkable Response to Paclitaxel and Carboplatin Combination Chemotherapy
View through CrossRef
Papillary serous carcinoma of the uterine cervix (PSCC) is a very rare, recently described variant of cervical adenocarcinoma. This review, describes a case of stage IV PSCC whose main tumor existed in the uterine cervix and invaded one third of the inferior part of the anterior and posterior vaginal walls. Furthermore, it had metastasized from the para-aortic lymph nodes to bilateral neck lymph nodes. Immnoreactivity for CA125 was positive, whereas the staining for p53 and WT-1 were negative in both the original tumor and the metastatic lymph nodes. Six cycles of paclitaxel and carboplatin combination chemotherapy were administered and the PSCC dramatically decreased in size. The main tumor of the uterine cervix showed a complete response by magnetic resonance imaging (MRI), and on rebiopsy, more than 95% of the tumor cells in the cervix had microscopically disapperared. This is the first report of PSCC in which combination chemotherapy was used and showed a remarkable response.
Title: Advanced Papillary Serous Carcinoma of the Uterine Cervix: A Case with a Remarkable Response to Paclitaxel and Carboplatin Combination Chemotherapy
Description:
Papillary serous carcinoma of the uterine cervix (PSCC) is a very rare, recently described variant of cervical adenocarcinoma.
This review, describes a case of stage IV PSCC whose main tumor existed in the uterine cervix and invaded one third of the inferior part of the anterior and posterior vaginal walls.
Furthermore, it had metastasized from the para-aortic lymph nodes to bilateral neck lymph nodes.
Immnoreactivity for CA125 was positive, whereas the staining for p53 and WT-1 were negative in both the original tumor and the metastatic lymph nodes.
Six cycles of paclitaxel and carboplatin combination chemotherapy were administered and the PSCC dramatically decreased in size.
The main tumor of the uterine cervix showed a complete response by magnetic resonance imaging (MRI), and on rebiopsy, more than 95% of the tumor cells in the cervix had microscopically disapperared.
This is the first report of PSCC in which combination chemotherapy was used and showed a remarkable response.
Related Results
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
 Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models
Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models
Abstract
ARQ087 is a non ATP-competitive tyrosine kinase inhibitor with activity against the FGFR receptor family, and currently in Phase I clinical studies for the ...
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract
Targeted osmotic lysis (TOL), the concurrent stimulation of voltage-gated sodium channels (VGSCs) and blockade of Na+ pumps, kills up to 100% of highly mali...
Abstract 1416: Synergistic cytotoxicity of metformin cotreatment with paclitaxel or carboplatin in triple negative breast cancer cell lines
Abstract 1416: Synergistic cytotoxicity of metformin cotreatment with paclitaxel or carboplatin in triple negative breast cancer cell lines
Abstract
Metformin is an oral antidiabetic drug with a putative antineoplastic effect in breast cancer; however, its efficacy in clinical trials has been mixed. Trip...
Delayed hypersensitivity and cytokine release syndrome to paclitaxel and nab-paclitaxel: a case report
Delayed hypersensitivity and cytokine release syndrome to paclitaxel and nab-paclitaxel: a case report
Hypersensitivity reactions (HSRs) to paclitaxel, particularly those mediated by the solubilizer Cremophor® EL, are common, occurring in approximately 10% of patients despite premed...
Relationship between serum NDRG3 and papillary thyroid carcinoma
Relationship between serum NDRG3 and papillary thyroid carcinoma
BackgroundIn recent years, papillary thyroid carcinoma is considered to be one of the fastest increaseing cancer. NDRG family member 3 (NDRG3) has been proposed as a molecular mark...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...

